



## Metabolomics-Driven Drug Discovery and Evaluation

Guest Editors:

**Dr. Fengguo Xu**

School of Pharmacy and MOE  
Key Laboratory of Drug Quality  
Control & Pharmacovigilance,  
China Pharmaceutical University,  
24 Tongjia Lane, Nanjing 210009,  
China

**Dr. Jianbo Wan**

Institute of Chinese Medical  
Sciences (ICMS) and State Key  
Laboratory of Quality Research in  
Chinese Medicine, University of  
Macau, Research Building N22  
Avenida da Universidade, Taipa,  
Macau, China

Deadline for manuscript  
submissions:

**closed (10 July 2023)**

### Message from the Guest Editors

Dear Colleagues,


Over the past few decades, metabolomics have evolved from a pure exploratory tool to a more mature quantitative biochemical technology. Metabolomics has now become an accepted and widely applied approach in drug development and evaluation. Functional metabolomics can help to find targets for drug development, suggest the mechanism of drug action, and indicate binding partners of compounds. Pharmacometabolomics play a crucial role in therapeutic drug monitoring (TDM) and clinical individualized drug therapy. Meanwhile, biologically active metabolites are a valuable resource for the development of drug candidates.

This Special Issue seeks novel research contributions in, but not limited to, the following areas:

- Targets discovery for drug development;
- Mechanism of drug action;
- Metabolomics “Big Data” driven strategy for drug discovery;
- Drug individual response;
- The function of biologically active metabolites;
- Drug repurposing;
- Pharmaceutical applications of metabolomics.

We welcome and look forward to your submissions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Dr. Amedeo Lonardo

Internal Medicine, Ospedale  
Civile di Baggiovara, Azienda  
Ospedaliero-Universitaria, 41126  
Modena, Italy

## Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

## Contact Us

*Metabolites* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/metabolites](http://mdpi.com/journal/metabolites)  
[metabolites@mdpi.com](mailto:metabolites@mdpi.com)  
✉@MetabolitesMDPI